GAS6/TAM Axis as Therapeutic Target in Liver Diseases

Semin Liver Dis. 2024 Feb;44(1):99-114. doi: 10.1055/a-2275-0408. Epub 2024 Feb 23.

Abstract

TAM (TYRO3, AXL, and MERTK) protein tyrosine kinase membrane receptors and their vitamin K-dependent ligands GAS6 and protein S (PROS) are well-known players in tumor biology and autoimmune diseases. In contrast, TAM regulation of fibrogenesis and the inflammation mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and, ultimately, liver cancer has recently been revealed. GAS6 and PROS binding to phosphatidylserine exposed in outer membranes of apoptotic cells links TAMs, particularly MERTK, with hepatocellular damage. In addition, AXL and MERTK regulate the development of liver fibrosis and inflammation in chronic liver diseases. Acute hepatic injury is also mediated by the TAM system, as recent data regarding acetaminophen toxicity and acute-on-chronic liver failure have uncovered. Soluble TAM-related proteins, mainly released from activated macrophages and hepatic stellate cells after hepatic deterioration, are proposed as early serum markers for disease progression. In conclusion, the TAM system is becoming an interesting pharmacological target in liver pathology and a focus of future biomedical research in this field.

MeSH terms

  • Axl Receptor Tyrosine Kinase*
  • Humans
  • Inflammation
  • Liver Cirrhosis / drug therapy
  • Proto-Oncogene Proteins* / metabolism
  • Proto-Oncogene Proteins* / therapeutic use
  • Receptor Protein-Tyrosine Kinases / metabolism
  • c-Mer Tyrosine Kinase / metabolism

Substances

  • c-Mer Tyrosine Kinase
  • Axl Receptor Tyrosine Kinase
  • Proto-Oncogene Proteins
  • Receptor Protein-Tyrosine Kinases

Grants and funding

Funding This research was funded by Instituto de Salud Carlos III (Project# PI22/00475 to M.M.) and by Ministerio de Ciencia e Innovación (PID2021-123564OB-I00, MCIN/AEI/10.13039/501100011033 to A.M. and P.G.F.), and co-funded by the European Union “ERDF A Way of Making Europe” (Next Generation EU/PRTR); CIBERCV; AGAUR (2021_SGR_490) and CERCA Programme/Generalitat de Catalunya; and Fundació la Marató de TV3 (202133-32) to A.M. and P.G.F. This research also received research funding and Sponsored Research Agreement, from BerGenBio ASA.